| 5.8169 0.317 (5.76%) | 10-22 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 7.5 | 1-year : | 8.4 |
| Resists | First : | 6.42 | Second : | 7.19 |
| Pivot price | 6.11  |
|||
| Supports | First : | 5.17 | Second : | 4.3 |
| MAs | MA(5) : | 5.77 |
MA(20) : | 6.25 |
| MA(100) : | 7.12 |
MA(250) : | 7.09 |
|
| MACD | MACD : | -0.4 |
Signal : | -0.3 |
| %K %D | K(14,3) : | 23.9 |
D(3) : | 30.2 |
| RSI | RSI(14): 38.4 |
|||
| 52-week | High : | 9.6 | Low : | 4.13 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ LFWD ] has closed above bottom band by 27.2%. Bollinger Bands are 2% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 5.94 - 5.98 | 5.98 - 6.02 |
| Low: | 5.37 - 5.42 | 5.42 - 5.46 |
| Close: | 5.74 - 5.82 | 5.82 - 5.89 |
Lifeward Ltd. is a healthcare technology company specializing in the creation, development, and commercialization of wearable robotic exoskeletons. These sophisticated devices are engineered to restore lower limb mobility for individuals living with spinal cord injuries (SCI), granting them the ability to stand, walk, pivot, and navigate staircases by providing assistive hip and knee motion. Key offerings from the company include the ReWalk Exo-Suit and the ReWalk Personal 6.0. Founded by Amit Goffer on June 20, 2001, the enterprise maintains its corporate headquarters in Marlborough, Massachusetts.
Wed, 14 Oct 2026
Seven people with paralysis used a walking aid at home for years. No falls or device-related fractures were reported. - Stock Titan
Thu, 08 Oct 2026
The CFO due to start November 1 won't join Lifeward (LFWD). - Stock Titan
Thu, 08 Oct 2026
Lifeward CFO nominee Rami Aviram declines; Josh Hexter to continue as interim - TradingView
Fri, 14 Aug 2026
Lifeward Ltd. 2026: Revenue $6.62M, Net income ($11.52M), EPS ($4.12) — 10-Q Summary - TradingView
Fri, 14 Aug 2026
Lifeward Revenue Rises 16% to $6.6 Million in Second Quarter 2026 | LFWD Stock News - Quiver Quantitative
Fri, 14 Aug 2026
Lifeward Reports Strong Second Quarter 2026 Financial Results as Commercial Execution Drives Growth - GlobeNewswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 3 (M) |
| Shares Float | 2 (M) |
| Held by Insiders | 47.1 (%) |
| Held by Institutions | 1.4 (%) |
| Shares Short | 97 (K) |
| Shares Short P.Month | 112 (K) |
| EPS | -15.73 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 4.32 |
| Profit Margin | -141.3 % |
| Operating Margin | -62.7 % |
| Return on Assets (ttm) | -47.3 % |
| Return on Equity (ttm) | -225.7 % |
| Qtrly Rev. Growth | 15.6 % |
| Gross Profit (p.s.) | 2.77 |
| Sales Per Share | 7.71 |
| EBITDA (p.s.) | -8.13 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -17 (M) |
| Levered Free Cash Flow | -8 (M) |
| PE Ratio | -0.37 |
| PEG Ratio | 0 |
| Price to Book value | 1.34 |
| Price to Sales | 0.75 |
| Price to Cash Flow | -0.97 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|